Saturday, 31 October 2026European Markets

GRIEG SEAFOOD, SALMAR, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Farm Products Industry.

Loading stream...

(VIANEWS) - GRIEG SEAFOOD (GSF.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Farm Products industry.

Financial Asset Price Forward Dividend Yield Return on Equity
GRIEG SEAFOOD (GSF.OL) kr87.90 5.02% 13.38%
SALMAR (SALM.OL) kr498.70 3.86% 20.22%
FRØY (FROY.OL) kr69.80 2.28% 6.67%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. GRIEG SEAFOOD (GSF.OL)

5.02% Forward Dividend Yield and 13.38% Return On Equity

Grieg Seafood ASA, through its subsidiaries, operates as a fish farming company in Norway, rest of Europe, the United States, Canada, Asia, and internationally. It engages in the production and sale of Atlantic salmon. The company was founded in 1884 and is headquartered in Bergen, Norway. Grieg Seafood ASA operates as a subsidiary of Grieg Aqua AS.

Earnings Per Share

As for profitability, GRIEG SEAFOOD has a trailing twelve months EPS of kr7.56.

PE Ratio

GRIEG SEAFOOD has a trailing twelve months price to earnings ratio of 11.63. Meaning, the purchaser of the share is investing kr11.63 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.38%.

More news about GRIEG SEAFOOD.

2. SALMAR (SALM.OL)

3.86% Forward Dividend Yield and 20.22% Return On Equity

SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, North America, Europe, and internationally. The company operates through Fish Farming, Sales & Industry, Icelandic Salmon, and SalMar Aker Ocean segments. It is involved in the broodstock, lumpfish, and smolt production activities; and marine-phase farming, harvesting, processing, and selling farmed salmon. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.

Earnings Per Share

As for profitability, SALMAR has a trailing twelve months EPS of kr31.38.

PE Ratio

SALMAR has a trailing twelve months price to earnings ratio of 15.89. Meaning, the purchaser of the share is investing kr15.89 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.22%.

More news about SALMAR.

3. FRØY (FROY.OL)

2.28% Forward Dividend Yield and 6.67% Return On Equity

Frøy ASA provides integrated service to the aquaculture industry in Norway. The company offers wellboat services, sea freight, de-lice and treatment, mooring and laying, ring washing and cage services, inspection and certification, bottom mapping and documentation, tow, and ROV and diving services, as well as drainage, inspection, and repair services. It owns and operates 19 wellboats, 64 aqua service vessels, and 3 feed transport vessels. The company was founded in 2019 and is headquartered in Sistranda, Norway.

Earnings Per Share

As for profitability, FRØY has a trailing twelve months EPS of kr2.6.

PE Ratio

FRØY has a trailing twelve months price to earnings ratio of 26.85. Meaning, the purchaser of the share is investing kr26.85 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.67%.

Volume

Today's last reported volume for FRØY is 29159 which is 60.76% below its average volume of 74321.

Revenue Growth

Year-on-year quarterly revenue growth grew by 19.5%, now sitting on 2.2B for the twelve trailing months.

Sales Growth

FRØY's sales growth is 11.8% for the present quarter and 4.1% for the next.

More news about FRØY.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com